At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CNTX Context Therapeutics Inc.
Market Closed 07-17 16:00:00 EDT
0.6000
-0.0146
-2.38%
盘后0.6120
+0.0120+2.00%
19:29 EDT
High0.6300Low0.6000Vol746.83K
Open0.6000D1 Closing0.6146Amplitude4.88%
Mkt Cap55.13MTradable Cap25.69MTotal Shares91.88M
T/O456.70KT/O Rate1.74%Tradable Shares42.82M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Context Therapeutics Grants New Hire Stock Options for 146,000 Shares at $0.7 Each
Reuters  ·  07-11
Context Therapeutics Grants New Hire Stock Options for 146,000 Shares at $0.7 Each
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  07-11
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst
TIPRANKS  ·  07-10
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
THOMSON REUTERS  ·  07-07
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
Context Therapeutics Shareholders Approve Increase in Authorized Common Shares to 300 Million
Reuters  ·  06-27
Context Therapeutics Shareholders Approve Increase in Authorized Common Shares to 300 Million
Context Therapeutics selloff brings buying opportunity, says JonesResearch
TIPRANKS  ·  06-16
Context Therapeutics selloff brings buying opportunity, says JonesResearch
Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI) and Context Therapeutics (CNTX)
TIPRANKS  ·  06-16
Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI) and Context Therapeutics (CNTX)
Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright
TIPRANKS  ·  06-16
Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data
TIPRANKS  ·  06-15
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data
Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial
TIPRANKS  ·  06-15
Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial
Context Therapeutics reports 29% response rate in Phase 1 trial of CTIM-76 for platinum-resistant ovarian cancer
Reuters  ·  06-15
Context Therapeutics reports 29% response rate in Phase 1 trial of CTIM-76 for platinum-resistant ovarian cancer
Context Therapeutics Announces Positive Interim Efficacy and Safety Results From Ongoing Phase 1 Clinical Trial for Ctim-76
THOMSON REUTERS  ·  06-15
Context Therapeutics Announces Positive Interim Efficacy and Safety Results From Ongoing Phase 1 Clinical Trial for Ctim-76
Context Therapeutics - Ctim-76 Granted FDA Fast Track Designation in Proc
THOMSON REUTERS  ·  06-15
Context Therapeutics - Ctim-76 Granted FDA Fast Track Designation in Proc
Context Therapeutics - Reports 29% Confirmed Overall Response Rate in Proc Patients With Median 7 Prior Therapies
THOMSON REUTERS  ·  06-15
Context Therapeutics - Reports 29% Confirmed Overall Response Rate in Proc Patients With Median 7 Prior Therapies
Context Therapeutics grants new hire stock options for 146,000 shares at USD 1.71 each
Reuters  ·  06-10
Context Therapeutics grants new hire stock options for 146,000 shares at USD 1.71 each
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-10
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  06-10
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics grants new hire stock options for 146,000 shares at USD 2.63 each
Reuters  ·  05-27
Context Therapeutics grants new hire stock options for 146,000 shares at USD 2.63 each
Context Therapeutics Decline Means Insider Profits Down To US$237k
Simply Wall St.  ·  05-19
Context Therapeutics Decline Means Insider Profits Down To US$237k
Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Context Therapeutics (CNTX)
TIPRANKS  ·  05-19
Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Context Therapeutics (CNTX)

Introduction

Company Name.
Context Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Issue price:
--